Literature DB >> 32567089

Effectiveness of mandatory peer review to reduce antipsychotic prescriptions for Medicaid-insured children.

Ayse Akincigil1,2, Thomas I Mackie2,3, Sharon Cook2, Robert J Hilt4, Stephen Crystal2.   

Abstract

BACKGROUND: Prior authorization of prescription medications is a policy tool that can potentially impact care quality and patient safety.
OBJECTIVE: To examine the effectiveness of a mandatory peer-review program in reducing antipsychotic prescriptions among Medicaid-insured children, accounting for secular trends that affected antipsychotic prescribing nationally. DATA SOURCE: Medicaid Analytical eXtracts (MAX) with administrative claims for health services provided between January 2006 and December 2011. STUDY
DESIGN: This retrospective, observational study examined prescription claims records from Washington State (Washington) and compared them to a synthetic control drawing from 20 potential donor states that had not implemented any antipsychotic prior authorization program or mandatory peer review for Medicaid-insured children during the study period. This method provided a means to control for secular trends by simulating the antipsychotic use trajectory that the program state would have been expected to experience in the absence of the policy implementation. PRINCIPAL
FINDINGS: Before the policy implementation, antipsychotic use prevalence closely tracked those of the synthetic control (6.17 per 1000 in Washington vs. 6.21 in the synthetic control group). Within two years after the policy was implemented, prevalence decreased to 4.04 in Washington and remained stable in the synthetic control group (6.47), corresponding to an approximately 38% decline.
CONCLUSION: Prior authorization program designs and implementations vary widely. This mandatory peer-review program, with an authorization window and two-stage rollout, was effective in moving population level statistics toward safe and judicious use of antipsychotic medications in children. © Health Research and Educational Trust.

Entities:  

Keywords:  Medicaid; antipsychotic medications; children and adolescents; mandatory peer review; prior authorization; synthetic control method

Mesh:

Substances:

Year:  2020        PMID: 32567089      PMCID: PMC7375997          DOI: 10.1111/1475-6773.13297

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  16 in total

1.  The effects of prior authorization policies on medicaid-enrolled children's use of antipsychotic medications: evidence from two mid-Atlantic states.

Authors:  Bradley D Stein; Emily Leckman-Westin; Edward Okeke; Deborah M Scharf; Mark Sorbero; Qingxian Chen; Ka Ho Brian Chor; Molly Finnerty; Jennifer P Wisdom
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-08-21       Impact factor: 2.576

Review 2.  Telemedicine for Child Collaborative or Integrated Care.

Authors:  Robert J Hilt
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2017-06-29

3.  Pediatric Use of Antipsychotic Medications Before and After Medicaid Peer Review Implementation.

Authors:  Julie M Zito; Mehmet Burcu; Stephen McKean; Rob Warnock; Jeffrey Kelman
Journal:  JAMA Psychiatry       Date:  2018-01-01       Impact factor: 21.596

4.  Internal validation of Medicaid Analytic eXtract (MAX) data capture for comprehensive managed care plan enrollees from 2007 to 2010.

Authors:  Yan Li; Yanmin Zhu; Chao Chen; Xi Wang; Yoonyoung Choi; Carl Henriksen; Almut G Winterstein
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-12-06       Impact factor: 2.890

5.  Effectiveness of mandatory peer review to reduce antipsychotic prescriptions for Medicaid-insured children.

Authors:  Ayse Akincigil; Thomas I Mackie; Sharon Cook; Robert J Hilt; Stephen Crystal
Journal:  Health Serv Res       Date:  2020-06-21       Impact factor: 3.402

6.  Decrease in Statewide Antipsychotic Prescribing after Implementation of Child and Adolescent Psychiatry Consultation Services.

Authors:  Rebecca P Barclay; Robert B Penfold; Donna Sullivan; Lauren Boydston; Julia Wignall; Robert J Hilt
Journal:  Health Serv Res       Date:  2017-04       Impact factor: 3.402

7.  Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom.

Authors:  Fariz Rani; Macey L Murray; Patrick J Byrne; Ian C K Wong
Journal:  Pediatrics       Date:  2008-05       Impact factor: 7.124

8.  Rapid Growth Of Antipsychotic Prescriptions For Children Who Are Publicly Insured Has Ceased, But Concerns Remain.

Authors:  Stephen Crystal; Thomas Mackie; Miriam C Fenton; Shahla Amin; Sheree Neese-Todd; Mark Olfson; Scott Bilder
Journal:  Health Aff (Millwood)       Date:  2016-06-01       Impact factor: 6.301

9.  National trends in the office-based treatment of children, adolescents, and adults with antipsychotics.

Authors:  Mark Olfson; Carlos Blanco; Shang-Min Liu; Shuai Wang; Christoph U Correll
Journal:  Arch Gen Psychiatry       Date:  2012-12

10.  A three-country comparison of psychotropic medication prevalence in youth.

Authors:  Julie M Zito; Daniel J Safer; Lolkje T W de Jong-van den Berg; Katrin Janhsen; Joerg M Fegert; James F Gardner; Gerd Glaeske; Satish C Valluri
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2008-09-25       Impact factor: 3.033

View more
  3 in total

1.  Effectiveness of mandatory peer review to reduce antipsychotic prescriptions for Medicaid-insured children.

Authors:  Ayse Akincigil; Thomas I Mackie; Sharon Cook; Robert J Hilt; Stephen Crystal
Journal:  Health Serv Res       Date:  2020-06-21       Impact factor: 3.402

2.  The Complexity of Psychotropic Medication Prescription and Treating Trauma Among Youth in Foster Care: Perspectives from the Lived Experience.

Authors:  Cadence F Bowden; Cassandra Simmel; Alicia Mendez; Melanie Yu; Sheree Neese-Todd; Stephen Crystal
Journal:  Adm Policy Ment Health       Date:  2022-06-28

3.  Trends Over Time in Antipsychotic Initiation at a Large Children's Health Care System.

Authors:  Laura J Chavez; Kelly J Kelleher; Arne Beck; Gregory N Clarke; Robert B Penfold
Journal:  J Child Adolesc Psychopharmacol       Date:  2021-06       Impact factor: 3.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.